The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Regular medical monitoring ensures the effectiveness of PrEP, with minimal side effects for most users. Additionally, HIV-positive individuals can benefit from treatment as prevention (TasP).

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

A six-month HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a challenge ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

The key to HIV treatment as prevention is meds you’ll take daily. The regimen itself is called antiretroviral therapy, or ART. It’s ideal to start as soon as you’ve been diagnosed.

HIV/AIDS : Welcome to Medscape HIV/AIDS, where you can peruse the latest medical news, commentary from clinician experts, major conference coverage, full-text journal articles, and trending stories.

For decades, HIV prevention relied on daily pills, but science has made incredible strides. The drug Lenacapavir, originally used for HIV treatment, has been shown to work as PrEP.

HIV prevention drugs cost $30 a month without insurance or are free with insurance. The drugs are safe and effective. But people have to learn how to access them, and that key component of the CDC ...

A CDC webpage says that in the 2023 fiscal year, Congress appropriated roughly $1.3 billion for the CDC’s HIV, viral hepatitis, STD and tuberculosis prevention budget.